Oncology Central

FDA approves TIBSOVO® for acute myeloid leukemia subtype

0
The FDA has granted approval for the first oral, targeted therapy for relapsed/ refractory acute myeloid leukemia (R/R AML) adults patients and an IDH1 mutation as detected by an FDA approved test. The approval of TIBSOVO® (ivosidenib) is based on Phase I study results.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Articles

Insights

Interviews

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.